Table 1. Baseline characteristics.
Characteristic | Number (%) |
---|---|
Age, yrs. | |
Median | 50.9 |
Range | 26–87 |
T stage | |
T1 | 163 (51.1) |
T2 | 148 (46.4) |
T3 | 5 (1.6) |
T4 | 3 (0.9) |
N stage | |
N0 | 183 (57.4) |
N1 | 91 (28.5) |
N2 | 24 (7.5) |
N3 | 21 (6.6) |
Histologic subtype | |
No special type | 288 (90.3) |
Lobular | 6 (1.9) |
Micropapillary | 5 (1.6) |
Metaplastic | 9 (2.8) |
Mucinous | 7 (2.2) |
Others | 4 (1.3) |
Histologic grade | |
I | 45 (14.1) |
II | 94 (29.5) |
III | 180 (56.4) |
LVI | |
Absent | 173 (54.2) |
Present | 146 (45.8) |
P53 overexpression | |
Negative | 221 (69.3) |
Positive | 98 (30.7) |
Ki-67 | |
< 20% | 166 (52.0) |
≥ 20% | 153 (48.0) |
ER | |
Negative | 98 (30.7) |
Positive | 221 (69.3) |
PR | |
Negative | 145 (45.5) |
Positive | 174 (54.5) |
HER2 | |
Negative | 238 (74.6) |
Positive | 81 (25.4) |
Subtype | |
Luminal A | 119 (37.3) |
Luminal B | 104 (32.6) |
HER2+ | 40 (12.5) |
Triple-negative | 56 (17.6) |
Adjuvant chemotherapy | |
Not received | 48 (15.0) |
Received | 265 (83.1) |
Unknown | 6 (1.9) |
Adjuvant radiotherapy | |
Not received | 137 (42.9) |
Received | 176 (55.2) |
Unknown | 6 (1.9) |
Adjuvant hormone therapy | |
Not received | 106 (33.2) |
Received | 207 (64.9) |
Unknown | 6 (1.9) |
LVI, lymphovascular invasion; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2